Cell Reprogramming Market To Reach $664.2 Million By 2030

Cell Reprogramming Market Growth & Trends

The global cell reprogramming market size is expected to reach USD 664.2 million by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 8.52% from 2024 to 2030. Factors, such as increasing adoption of cell reprogramming in cancer research and growing focus on cell reprogramming, are expected to drive market growth. In addition, emphasis on collaborations and partnerships among key players is anticipated to boost market growth. Advancements in the mRNA reprogramming technique allow rapid, safe, and efficient generation of clinical-grade human iPS cells using somatic tissue. In addition, as mRNA is lower in size, the transfection process is simpler than other reprogramming vectors. When utilizing difficult-to-reprogram samples, mRNA reprogramming improves reprogramming efficiency by 1%.

Furthermore, this method can generate high-quality human iPS cells from somatic tissue more rapidly and safely, which increases the demand for mRNA reprogramming technology. Furthermore, there is the capability to reprogram human stem cells back to a naive state, allowing replication of the earliest developmental stages. For instance, in March 2022, researchers at the Babraham Institute identified key factors facilitating this reprogramming process. This new knowledge streamlines and expedites the generation of naive pluripotent stem cells for researchers. Moreover, cell reprogramming is experiencing growth due to significant government and public funding. This backing is a response to various benefits it offers to the healthcare sector, particularly in terms of its potential applications in medicine.

Furthermore, cell reprogramming has recently been repositioned from the lab to clinic by researchers. This shift is prominent in various clinical & academic research initiatives, encompassing regenerative medicine, disease modeling, and studies related to medication toxicity & drug discovery. The clinical utility of cell reprogramming, especially in regenerative medicine, has been significant. Increased strategic initiatives aimed at innovative product development through cell reprogramming is due to a growth in the research and academic institute segment. For instance, the California Institute for Regenerative Medicine funded research groups to advance cellular reprogramming into therapeutic applications with a clinical focus.

 Request a free sample copy or view report summary: Cell Reprogramming Market Report

Cell Reprogramming Market Report Highlights

• The mRNA reprogramming technology segment held the largest revenue share of 32.67% in 2023 due to the ease of use, speed, safety, and efficiency while generating high-quality human iPS cells from somatic tissue

• The research application segment led the market with a share of 67.41% in 2023. One of the main factors driving its growth include ongoing research in the field of cell reprogramming using stem cells

• The research & academic institute end-use segment held a revenue share of 67.41% in 2023. The growth is due to usage of cell reprogramming in a various clinical & academic research initiatives, including those involving regenerative therapies, disease modeling, and drug toxicity/drug discovery studies

• North America dominated the global industry in 2023 with a revenue share of 38.65% owing to the presence of key players in this region

Cell Reprogramming Market Segmentation

Grand View Research has segmented the global cell reprogramming market based on technology, application, end-use, and region:

Cell Reprogramming Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Sendai Virus-based Reprogramming

• mRNA Reprogramming

• Episomal Reprogramming

• Others

Cell Reprogramming Application Outlook (Revenue, USD Million, 2018 - 2030)

• Research

• Therapeutic

Cell Reprogramming End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Research & Academic Institutes

• Biotechnology & Pharmaceutical Companies

Cell Reprogramming Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East And Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Cell Reprogramming Market

• Thermo Fisher Scientific, Inc.

• Allele Biotech

• ALSTEM

• STEMCELL Technologies Inc.

• Merck KGaA

• Bio-Techne

• REPROCELL

• Lonza

• FUJIFILM Corporation (Fujifilm Cellular Dynamics)

• Mogrify Limited